Bringing plant-based veterinary vaccines to market: Managing regulatory and commercial hurdles
| Autor: | Ginny Jones, Jacqueline MacDonald, Rima Menassa, Larry A. Holbrook, Alex Richman, Andrew A. Potter, Heather Shearer, Edward Topp, Ketan Doshi, Angelo Kaldis, Phil Macdonald, Marike Dussault, Tim A. McAllister, Han Sang Yoo, Michael D. McLean, Oksana Yarosh, Cassidy L. Klima, J. Christopher Hall |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Veterinary medicine
Canada Scale-up Recombinant vaccine Bioengineering Intellectual property Applied Microbiology and Biotechnology Commercialization Freedom to operate Animal Diseases Human health Production (economics) Animals Humans Antibody Animal use Vaccines Synthetic Plant based Plants Immunotherapeutic Molecular farming Recombinant vaccines Business Financing Relevant information Biotechnology |
| Zdroj: | Biotechnology advances. 33(8) |
| ISSN: | 1873-1899 |
| Popis: | The production of recombinant vaccines in plants may help to reduce the burden of veterinary diseases, which cause major economic losses and in some cases can affect human health. While there is abundant research in this area, a knowledge gap exists between the ability to create and evaluate plant-based products in the laboratory, and the ability to take these products on a path to commercialization. The current report, arising from a workshop sponsored by an Organisation for Economic Co-operation and Development (OECD) Co-operative Research Programme, addresses this gap by providing guidance in planning for the commercialization of plant-made vaccines for animal use. It includes relevant information on developing business plans, assessing market opportunities, manufacturing scale-up, financing, protecting and using intellectual property, and regulatory approval with a focus on Canadian regulations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect